行情

DBVT

DBVT

DBV Tech
NASDAQ

实时行情|Nasdaq Last Sale

5.21
+0.19
+3.78%
盘后: 5.21 0 0.00% 16:00 03/05 EST
开盘
5.08
昨收
5.02
最高
5.22
最低
4.970
成交量
16.57万
成交额
--
52周最高
9.32
52周最低
1.350
市值
5.72亿
市盈率(TTM)
-2.7729
分时
5日
1月
3月
1年
5年
DBV Technologies宣布任命Michele F. Robertson为首席法律官
Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- Montrouge, France, February 22, 2021 DBV Technologies Announces Appointment of Michele F. Robertson as Chief...
GlobeNewswire · 02/22 06:30
DBV Technologies将参加SVB Leerink全球合作伙伴医疗保健会议
Feb 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Montrouge, France, February 19, 2021 DBV Technologies to Participate in SVB Leerink Global Partners Healthcare...
GlobeNewswire · 02/19 06:30
农业物联网市场研究报告按组件,按农业类型,按应用分类-到2025年的全球预测-COVID-19的累积影响
GlobeNewswire · 02/18 16:42
截至2021年1月31日有关公司表决权总数和股份总数的月度信息
Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- Monthly information regarding the total number of voting rights and total number of shares of the Company as of...
GlobeNewswire · 02/11 21:30
绝对报告称2021年血友病A药物市场规模研究报告按增长率,收入估算,市场动态,行业趋势和对2027年的预测
Feb 10, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Hemophilia A Drug Market” research report...
The Express Wire · 02/10 08:53
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Jan 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- AMF REGULATED INFORMATIONMontrouge, France, January 29, 2021 Half-Year Report on the DBV Technologies Liquidity...
GlobeNewswire · 01/29 21:30
DBV Technologies SA – American(DBVT)被Stifel Nicolaus保留
Stifel Nicolaus analyst Derek Archila maintained a Hold rating on DBV Technologies SA - American (DBVT) on January 4 and set a price target of $6.00. The
SmarterAnalyst · 01/22 09:04
最终用户的过敏类型,疫苗类型,应用,用途分类的过敏疫苗市场研究报告-到2025年的全球预测-COVID-19的累积影响
New York, Jan 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 01/19 12:22
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解DBVT最新的财务预测,通过DBVT每股收益,每股净资产,每股现金流等数据分析DBV Tech近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测DBVT价格均价为9.09,最高价位16.64,最低价为1.957。
EPS
机构持股
总机构数: 104
机构持股: 3,714.20万
持股比例: 33.81%
总股本: 1.10亿
类型机构数股数
增持
9
47.43万
建仓
23
-159.05万
减持
9
68.16万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+1.51%
制药与医学研究
+1.63%
高管信息
Chairman/Chief Executive Officer/Director
Pierre-Henri Benhamou
Chief Operating Officer
David Schilansky
Executive Vice President/General Counsel
Joan Schmidt
Chief Scientific Officer
Hugh Sampson
Vice President - Research & Development
Lucie Mondoulet
Vice President - Business Development
Nathalie Donne
Director of Marketing
Veronique Foutel
Other
Wence Agbotounou
Other
Bertrand Dupont
Other
Laurent Martin
Other
Pascale Ehouarn
Director
Michel de Rosen
Director
George Horner
Director
Mailys Ferrere
Director
Didier Hoch
Director
Chahra Louafi
Director
Rafaele Tordjman
暂无数据
DBVT 简况
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

微牛提供DBV Technologies SA(NASDAQ-DBVT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的DBVT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易DBVT股票基本功能。